A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors

被引：0
|
作者：
Tolcher, Anthony W.
Lakhani, Nehal J.
McKean, Meredith
Lingaraj, Trupti
Victor, Laura
Sanchez-Martin, Marta
Kacena, Katherine
Malek, Karim S.
Santillana, Sergio
机构：
[1] NEXT Oncol & Texas Oncol, San Antonio, TX USA
[2] START Midwest, Grand Rapids, MI USA
[3] Sarah Cannon Res Inst, Tennessee Oncol, PLLC, Nashville, TN USA
[4] Ikena Oncol, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3168
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-in-human phase I study of an oral HSP9O inhibitor, TAS-116, in advanced solid tumors.
    Yanagitani, Noriko
    Horiike, Atsushi
    Kitazono, Satoru
    Ohyanagi, Fumiyoshi
    Kondo, Shunsuke
    Shimomura, Akihiko
    Fujiwara, Yutaka
    Doi, Toshihiko
    Kuboki, Yasutoshi
    Kawazoe, Akihito
    Shitara, Kohei
    Ohno, Izumi
    Banerji, Udai
    Sundar, Raghav
    Ohkubo, Shuichi
    Huang, Jerry M.
    Nishio, Makoto
    Yamamot, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.
    Sands, Jacob M.
    Shimizu, Toshio
    Garon, Edward B.
    Greenberg, Jonathan
    Guevara, Ferdinand M.
    Heist, Rebecca Suk
    Kobayashi, Fumiaki
    Noguchi, Yutaka
    Okajima, Daisuke
    Tajima, Naoyuki
    Spira, Alexander I.
    Yamamoto, Noboru
    Lisberg, Aaron Elliott
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
    Bauer, Todd
    Cho, Byong Chul
    Heist, Rebecca
    Bazhenova, Lyudmila
    Werner, Theresa
    Goel, Sanjay
    Kim, Dong-Wan
    Adkins, Douglas
    Carvajal, Richard D.
    Alva, Ajjai
    Eaton, Keith
    Wang, Judy
    Liu, Yong
    Yan, Xiaohong
    Christensen, Jamie
    Neuteboom, Saskia
    Chao, Richard
    Pant, Shubham
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 990 - 1000
  • [24] First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
    Todd Bauer
    Byong Chul Cho
    Rebecca Heist
    Lyudmila Bazhenova
    Theresa Werner
    Sanjay Goel
    Dong-Wan Kim
    Douglas Adkins
    Richard D. Carvajal
    Ajjai Alva
    Keith Eaton
    Judy Wang
    Yong Liu
    Xiaohong Yan
    Jamie Christensen
    Saskia Neuteboom
    Richard Chao
    Shubham Pant
    Investigational New Drugs, 2022, 40 : 990 - 1000
  • [25] A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and-2 Inhibitor, in Patients with Advanced Solid Tumors
    Dowlati, Afshin
    Vlahovic, Gordana
    Natale, Ronald B.
    Rasmussen, Erik
    Singh, Indrajeet
    Hwang, Yuying C.
    Rossi, John
    Bass, Michael B.
    Friberg, Gregory
    Pickett, Cheryl A.
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4574 - 4584
  • [26] First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors
    Patricia M. LoRusso
    Priscila H. Goncalves
    Lindsay Casetta
    Judith A. Carter
    Kevin Litwiler
    Dale Roseberry
    Selena Rush
    Jennifer Schreiber
    Heidi M. Simmons
    Mieke Ptaszynski
    Edward A. Sausville
    Investigational New Drugs, 2015, 33 : 440 - 449
  • [27] First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors
    LoRusso, Patricia M.
    Goncalves, Priscila H.
    Casetta, Lindsay
    Carter, Judith A.
    Litwiler, Kevin
    Roseberry, Dale
    Rush, Selena
    Schreiber, Jennifer
    Simmons, Heidi M.
    Ptaszynski, Mieke
    Sausville, Edward A.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 440 - 449
  • [28] A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors
    Doi, Toshihiko
    Takahashi, Shunji
    Aoki, Daisuke
    Yonemori, Kan
    Hara, Hiroki
    Hasegawa, Kosei
    Takehara, Kazuhiro
    Harano, Kenichi
    Yunokawa, Mayu
    Nomura, Hiroyuki
    Shimoi, Tatsunori
    Horie, Koji
    Ogasawara, Aiko
    Okame, Shinichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (06) : 605 - 616
  • [29] A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results.
    Capelan, Marta
    Kumar, Prasana
    Tolcher, Anthony W.
    Zivi, Andrea
    Desai, Madhuri
    Papadopoulos, Kyriakos P.
    Senaldi, Giorgio
    Patnaik, Amita
    Banerji, Udai
    Rasco, Drew D.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [30] First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors
    Hong, David S.
    LoRusso, Patricia
    Hamid, Omid
    Beaupre, Darrin M.
    Janku, Filip
    Khan, Rabla
    Kittaneh, Mualad
    Loberg, Robert D.
    Amore, Benny
    Caudillo, Isaac
    Hwang, Yuying C.
    Tang, Rui
    Mgarmchamnanrith, Gataree
    Kwak, Eunice Leo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345